Fulcrum Pharma

Larus joins Clinipace Worldwide

Tuesday, October 18, 2011 02:04 PM

Clinipace Worldwide has named John Larus executive vice president of clinical operations. In this newly created position, John reports directly to Chris Porter, chief operating officer, and is responsible for providing leadership and direction to the project management, clinical monitoring and safety groups within the U.S. clinical operations unit.

More... »

Aptiv Solutions acquires SRA Global Clinical Development

Thursday, October 6, 2011 01:08 PM

Reston, Va.-based Aptiv Solutions, which designs and executes adaptive clinical trials and medical device studies, has acquired SRA Global Clinical Development (GCD), the CRO division of SRA International, based in Durham, N.C., with offices in Paris, France and Milton Park, England.

More... »

Ricerca Biosciences collaborates with Fulcrum Pharma

Friday, March 4, 2011 02:13 PM

Ricerca Biosciences, a preclinical CRO, has partnered with Fulcrum Pharma, an Aptiv Solutions company and a provider of drug development consulting and regulatory services. The collaboration aims to help biopharmaceutical companies move a candidate from development to clinical evaluation more efficiently.

More... »

Four clinical research firms become one global services organization to target niche areas

Monday, September 20, 2010 07:18 AM

Four small and mid-sized clinical research service companies—Averion International, Trio Clinical Research, Fulcrum Pharma and Clin-Research/ADDPLAN—have merged into one global biopharmaceutical and medical device development services organization that will focus on niche areas, including adaptive trials and new technologies, which can help sponsors make decisions about their drug candidates faster.

More... »

Investors to roll three acquisitions into one adaptive trials CRO

Monday, August 16, 2010 08:45 AM

More proof that the markets are improving: equity investors the Halifax Group and SV Life Sciences have acquired three companies that they will roll up into one, yet-to-be-named, adaptive trials-focused, CRO-like entity.

More... »